https://european-biotechnology.net/wp-content/uploads/2026/04/getty-images-X37jT1yreKs-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-23 15:57:592026-04-23 15:57:59Kurma Partners closes Biofund IV at €215M, giving European biotech a fresh specialist pool of capital
https://european-biotechnology.net/wp-content/uploads/2026/04/Proteins1-founders-1030x580-1.jpeg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-16 13:20:502026-04-16 13:20:50Proteins.1 launches with €4.7m to make protein detection as easy as PCR
https://european-biotechnology.net/wp-content/uploads/2026/04/spain-boston-fund-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-15 18:56:572026-04-15 18:56:57Spain plants US$200m flag in Boston with debut US biotech fund
https://european-biotechnology.net/wp-content/uploads/2026/04/getty-images-HZfsCshPpiE-unsplash-1030x579-1.jpg5791030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-15 09:42:372026-04-15 09:42:37Novo Nordisk is going all in on AI
https://european-biotechnology.net/wp-content/uploads/2026/04/Seite-22_Cedric-Moreau.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-04-15 08:36:472026-04-15 08:36:47Can Europe finance and keep its biotech winners?
